Kidney disease (autosomal dominant polycystic) - tolvaptan [ID652]: final appraisal determination

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Tolvaptan for treating autosomal dominant polycystic kidney disease and submitted it to the Institute.

It was identified following the Committee discussion that, because of a technical error in the NICE website, a number of public comments had not been retrieved. These comments had therefore not been made available to the Committee at the time of the appraisal committee meeting. Given the value NICE places on the consultation process and comments received from all stakeholders, these comments have been considered by the Committee during the development of the FAD. For completeness and transparency, these comments are included in the Committee papers available with the FAD.

The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors.  The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England.

Please note that the appeal period for this appraisal will close at 5pm on Friday 18 September 2015.

This page was last updated: 03 September 2015